bioRxivImmunologyPreprint
Spatiotemporal dynamics of adoptively transferred stem-like CD8+ T cells in the tumor microenvironment following vaccination
Dalton HermansiD, Sloane Christian FusselliD, Andrei Ramirez-Valdez, Sam ShepardiD, Remi PoulardiD, Sonia ZumalaveiD, Benjamin Louis SieversiD, Christopher M. GarlissiD, Vincent L. Coble, Geoffrey M. LynniD, Andrew S. IshizukaiD, Isidro Cortés‐CirianoiD, Robert A. SederiD
Abstract
Adoptive cell therapy (ACT) of tumor-specific T cells can improve survival in a subset of cancer patients. Current ACT approaches may be limited by using highly differentiated T cells which can be inhibited by an immunosuppressive tumor microenvironment (TME). Here, we developed an approach to optimize ACT and used spatial transcriptomics to show how stem-like and effector CD8+ T cells differentially mediate tumor control following vaccination. Spatial transcriptomic profiling of the TME showed that ACT with stem-like T cells followed by intravenous vaccination prevented immune exclusion, increased infiltration of pro-inflammatory macrophages, and reprogrammed tumor cells to upregulate Type I and Type II IFN signaling and apoptotic gene programs. The protective transcriptomic signature of the TME in this ACT model contained overlapping biomarkers with patients who responded to ACT therapy. This approach demonstrates synergy between transferred stem-like T cells and intravenous vaccination to transcriptionally remodel the TME and enhance tumor control.
- organism: mouse
- assay: spatial transcriptomics
- research focus: host-pathogen & immune response
- research focus: cell type annotation
- research focus: cell signaling & trafficking
- approach: experimental assay
- Citations
- 0
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A Transient Immunostimulatory Niche Synergizes Adoptive and Endogenous Immunity for Enhanced Tumor Control
Anahita Nejatfard, John H. Klich, … Eric Andrew Appel·bioRxiv·Aug 22, 2025
- Long-term efficacy of adoptive cell therapy is determined by host CD8+ T cells and undermined by lymphodepleting preconditioning
Diego A. Figueroa, Juan Pablo Vega, … Álvaro Lladser·bioRxiv·May 16, 2024
- CXCR3 on transferred T cells enables vaccine-boosted adoptive T-cell therapy in solid tumors
Vinnycius Pereira Almeida, Lucy C. Garner, … Carol Sze Ki Leung·bioRxiv·Oct 11, 2026
- TGF--dependent Lymphoid Tissue Residency of Stem-like T cells Limits the Response to Tumor Vaccine
- Actionable spatial prostanoid barriers constrain BiTE-driven adoptive T cell immunity in intact human tumors
Bovannak Stewen Chap, Tania Santoro, … Denarda Dangaj Laniti·bioRxiv·Mar 30, 2026
- Successful dendritic cell vaccines require lasting in-situ TNF α secretion to license antitumor CD8 + T cell cytotoxicity
Nadine Santana-Magal, Aseel Khateeb, … Yaron Carmi·bioRxiv·Apr 8, 2026